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Abstract
Background: Interleukin-1 receptor associated kinase 1 (IRAK1), as a down-stream of toll-like receptor (TLR)
signaling, plays important roles in series of malignancies. However, the role of IRAK1 in hepatocellular carcinoma
(HCC) remains little known.
Methods: In our study, reverse transcription-PCR (RT-PCR), Western Blot, and immunohistochemical staining were
used to assess the mRNA and protein levels of IRAK1 in clinical samples and cell lines. Cell counting assay and
flow cytometry were employed to analyze the effect of IRAK1 on cell cycle and apoptosis. Transwell assay was
used to study the role of IRAK1 in cell migration. Moreover, subcutaneous xenograft tumor models predict the
efficacy of targeting IRAK1 against HCC in vivo.
Results: IRAK1 was over-expressed in HCC tissues and cell lines. Suppression of IRAK1 by small interference RNA
(siRNA) or a pharmaceutical IRAK1/4 inhibitor impeded cell growth, induced apoptosis and lessened HCC xenograft
tumor growth. Particularly, IRAK1/4 inhibitor treatment caused G1/S cell cycle arrest and apoptosis, confirming IRAK1 as
a new therapeutic target for HCC.
Conclusion: IRAK1 promotes cell proliferation and protects against apoptosis in HCC, and can be a novel target
for HCC treatment.
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Background
Primary hepatocellular carcinoma (HCC), one of the
most common malignant solid tumors, is a prototype
of inflammation-related cancer due to a history of un-
controlled inflammation and cirrhosis, and most hu-
man HCC cases are related to inflammation and
cirrhosis [1–5]. Previous reports suggested that the
chronic damage and inflammation had closed rela-
tionship with carcinogenesis [6]. For example,
interleukin-1β (IL-1β) is a critical inflammatory cyto-
kine linking with chronic inflammation [7, 8]. The
gender difference of liver cancer is the result of sex-
associated differential production of IL-6, which relies
on IL-1R/IRAK-1 signaling [9]. In addition, IL-1β/IRAK-1
signaling contributes to persistent expression of oncogene
Gankyrin, and the later promotes HCC progression [8].
Aberrant IRAK1 expression has been shown in multiple
tumors, such as myeloma, leukemia and several types
of solid cancers. Accordingly, there has been much ef-
fort to target IRAK1 using pharmaceutical inhibitors
[10–12].
IRAK1, the first protein to be discovered in IRAK
family, is the main mediator of TLR/IL1R signal path-
ways. After IL1R/TLR binding, IRAK1 interacts with
MyD88, which could be rapidly recruited to the recep-
tor. The phosphorylation of IRAK1 is a multistep
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process and results in the activation of IRAK1. In this
process, the threonine 209 (T209) is vital for IRAK1
kinase activity [13–15]. Phosphorylated IRAK1 could
release from the receptor complex and bind to the E3
ubiquitin ligase and TRAF6. As the result, NF-kB signal
pathway is activated [16–18]. In some malignant tu-
mors, disordered inflammatory toll-like receptor (TLR)
signaling is related to up-regulated NF-kB activity. The
IRAK family members are mediators of TLR/IL1R sig-
nal pathways, and amounts of evidence implicate that
these kinases including IRAK1 are vital cancer targets
[19, 20]. IRAK1 is also related to the formation and
development of series of myeloid malignancies or
tumors, especially in myelodysplastic syndrome (MDS),
acute myeloid leukaemia (AML) [21], melanoma [22],
Lung Cancer [23, 24] and Breast cancer [25, 26]. How-
ever, the roles of IRAK1 in HCC have not been investi-
gated by now.
Given that IL-1R/MyD88/IRAK signaling plays a
critical role as a contributor to progression of HCC
[8], the goal of our study was to gain a greater
understanding of the significance of IRAK1 in the
growth and survival of HCC. We found that HCC
cells expressed elevated levels of IRAK1 mRNA as
well as protein levels of total IRAK1. Inhibition of
IRAK1 with siRNAs or a small molecular inhibitor
retarded cell proliferation. At a mechanistic level,
IRAK1 regulated G1/S phase of cell cycle and cell
apoptosis. The importance of targeting IRAK1 in
HCC was emphasized by demonstrating that treat-
ment with IRAK1 siRNAs suppressed HCC tumor
growth in xenograft model. Our study highlighted a
critical of IRAK1 in HCC proliferation and suggested
a pathophysiological role and clinical implication for
patients with HCC.
Methods
Reagents and cell lines
All chemical reagents were purchased from Sigma-Aldrich
(St Louis, MO, USA). The IRAK1/4 inhibitor, which se-
lectively inhibits the kinase activity of IRAK1 at the
IC50 of 0.75 mM and prevents TRAF6-mediated
canonical NF-kB activation, has been developed for
autoimmune disease and Myelodysplastic Syndrome
[27–29]. Here, the IRAK1/4 inhibitor (I5409) dissolved
in DMSO was used for the inhibition of p-IRAK1. Cis-
platin (Cis) and epirubicin (ADM) were used for stimu-
lating the cell apoptosis as previous report of our lab
[8]. HEK293T, MHCC-LM3, SMMU-7721, HepG2,
PLC/PRF/5 and PVTT cell lines were purchased from Cell
Bank of Type Culture Collection of Chinese Academy of
Sciences (Shanghai, China). Cells were grown in DMEM
(Life Technologies, Carlsbad, CA, USA) which was
supplemented with 10 % fetal bovine serum (FBS, Life
Technologies), 100 U/ml penicillin and 100 μg/ml
streptomycin, and at 37 °C with 5 % CO2.
HCC samples and immunohistochemical straining
About 33 HCC samples were collected from Eastern
Hepatobiliary Surgery Hospital (Shanghai, China) and
the procedure of human sample collection was approved
by the Ethical Committee of Eastern Hepatobiliary
Surgery Hospital. Immunohistochemical staining was
performed with total IRAK1 antibody (Santa Cruz, CA,
USA) and Ki67 antibody (Santa Cruz) as reported previ-
ously [8].
Lentivirus-mediated knockdown of IRAK1
Three si-IRAK1 lentiviruses were purchased from
Hanbio (Shanghai, China). MHCC-LM3 and SMMU-
7721 Cells were transfected with Si-IRAK1 lentivirus
at multiplicity of infection (MOI) of 0.5 ~ 1 at the cell
density of 105/ml. At 48 h after transfection, puro-
mycin was added to the cell medium for screening
positive cells.
Real-time PCR analysis
RNA was extracted with the Trizol reagent (Thermo
Fisher Scientific, Hudson, NH, USA) and reverse tran-
scription was carried out with SuperScript® IV Reverse
Transcriptase (Thermo Fisher Scientific). Real-time PCR
was performed with SYBR Green qPCR mix (Life Tech-
nologies) and Lightcycler 96 System (Roche Diagnostics,
Rotkreuz, Switzerland) while 18 s cDNA was used as the
reference.
Cell migration analysis
Cell migration assay was performed with transwell
chambers (Costar, Cambridge, MA) as the method of
Binhui Xie et al. [30]. For SMMU-7721 cell lines, about
2 × 105 cells were plated into the chamber with serum
free-DMEM medium. Then, the chamber were placed
into wells of the 12-well plate which was added with the
medium containing 10 % FBS. After incubation for 24 h,
the migrated cells were fixed with 4 % paraformaldehyde
and stained with crystal violet for 10 min.
CCK-8 and colony formation analysis
The CCK-8 analysis was carried out according to the in-
struction of Cell Counting Kit-8 (CCK-8, Dojindo,
Tokyo, Japan). Briefly, IRAK1 inhibitor at concentrations
of 0, 10, 20 μM were added into SMMU-7721, HepG2,
PLC/PRF/5 and PVTT for 1–5 days. Then, 1/10 diluted
CCK-8 solution with DMEM was added into the target
wells of 96-well plate after discarding the culture
medium, following the incubation for 1 h and measure-
ment using a microplate reader (Bio-Rad Laboratories,
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Hercules, CA). Cell proliferation rates were calculated
and normalization with the OD value of 1st day.
Colony formation analysis was carried out in SMMU-
7721 and HepG2 cell lines. The cells were plated into a
6-well plate (3 × 103 cells per well) and incubated for
12 days. Cells were fixed with 4 % para-formaldehyde
and stained with crystal violet.
Cell cycle and apoptosis analysis
SMMU-7721 were plated into the 6-well plate and cul-
tured in serum-free DMEM medium for 12 h in order to
synchronize cells. Then the medium was changed into
DMEM medium with 10 % FBS. After 24 h or 48 h, the
cells were fixed with 70 % ethanol at 4 °C for more than
4 h and then washed by phosphate buffered saline (PBS).
In order to remove RNA, RNase A (1 mg/ml of final
concentration) was used to digest the fixed cells for
30 min. Then, the staining was carried out with 50 μg/ml
propidium iodide (PI) in PBS-Triton X-100 for another
20 min at 4 °C. Finally, results were acquired by the flow
cytometer (Life Technologies) analysis.
The cell apoptosis analysis was carried out with the
previous method [31]. After treated with IRAK1/4 in-
hibitor (20 μM) for 24 h and 48 h, SMMU-7721 cells
were stained with the Annexin V/PI kit (Life technology)
according to the instruction. Cell apoptosis was detected
and analyzed by the flow cytometer.
Nucleocytoplasmic separation
The nucleocytoplasmic separation was carried out with
the NE-PER nuclear and cytoplasmic extract Kit
(Thermo Fisher Scientific). As the method described in
this kit, SMMU-7721-SiIRAK1-1 and SMMU-7721-NC
cell lines were cultured and harvested for extracting the
cytoplasmic and nuclear proteins after stimulated by cis-
platin (Cis) and epirubicin (ADM) for cell apoptosis. P65
was detected with Western Blot analysis while Histone
H3 and GAPDH as the internal control.
Western blot analysis
As the previously described methods [8], proteins (30 μg/
lane) were isolated by SDS-PAGE electrophoresis and
then transferred to NC membranes. Then, the membranes
were blocked with 5 % milk in Tris–HCl buffer and
0.05 % Tween-20 (TBS/Tween) for 1 h and incubated with
primary antibodies against total IRAK1(Santa Cruz),
phosphorylated-IRAK-1 (Ser 209) (Cell Signaling Tech-
nology, Danvers, MA, USA), P65 (Cell Signaling Technol-
ogy), GAPDH (Cell Signaling Technology), Histone H3
(Cell Signaling Technology) and β-actin (Cell Signaling
Technology) overnight at 4 °C. Subsequently, the mem-
brane was incubated with fluorescence-conjugated sec-
ondary antibody (Cell Signaling Technology) and
scanned with Odyssey scanner (LI-COR Biosciences,
Lincoln, Nebraska).
In vivo subcutaneous tumor model
Five weeks old male nude mice were purchased from
Shanghai Experimental Animal Center (Shanghai, China)
and fed in Experimental Animal Center of Second Mili-
tary Medical University (Shanghai, China). All animal
experiments were carried out according to the directions
of Second Military Medical University Animal Care
Facility and the National Institutes of Health guidelines.
SMMU-7721-SiIRAK1-1 and SMMU-7721-NC cell lines
were cultured and subcutaneously injected at 5 × 106
cells/nude mouse. About two months later, six nude
mice were sacrificed for harvesting subcutaneous tumor.
At last, the subcutaneous tumor samples were analyzed
by immunohistochemical straining with the Ki67 anti-
body (Cell Signaling Technology).
For the IRAK1/4 inhibitor treatment, the IRAK1/4
inhibitor was dissolved in DMSO at the concentration of
5 mM, and further diluted in PBS. The SMMU-7721 cell
line was implanted subcutaneously in mice and allowed
to grow until the tumors reached a size of approximately
150 mm3. In vivo delivery of the IRAK1/4 inhibitor ap-
proach is adapted from previous reports of Yang. et al.
[29] and Rhyasen GW. et al. [20], xenografted mice were
randomized and injected i.p. with 2.12 mg/kg IRAK1/4
inhibitor four times per week for two weeks.
Statistical analysis
All experiments were repeated for three times and the
data analysis was performed with student T-test and
two-way ANOVA analysis with GraphPad software.
Tumor volumes from two groups in subcutaneous HCC
models were analyzed by two-way ANOVA analysis. The
data were presented as the mean ± SEM. P < 0.05 was
considered statistically significant.
Results
IRAK1 was over-expressed in HCC tumor tissues
The mRNA and protein level of IRAK1 was investi-
gated in 33 clinical HCC specimens. We found that
IRAK1 was highly expressed in the HCC tissues com-
paring with adjacent normal tissues by immunohisto-
chemical staining (Fig. 1a). IRAK1 was mostly located
in the cytoplasm, while some existed in nucleus.
Increased IRAK1 mRNA levels were comparable to
those in non-malignant tissues (Fig. 1b). As is showed
in Fig. 1c and d, increased protein levels of IRAK1 was
detected in 12 HCC biopsies, suggesting that IRAK1
was over-expressed in most HCC specimens.
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Knockdown of IRAK1 reduced HCC cell growth
To investigate the role of IRAK1 in HCC cell growth,
the protein levels of IRAK1 in liver cancer cell lines were
examined, including PLC/PRF/5, Huh7, HepG2, SMMU-
7721 and MHCC-LM3. As shown in Fig. 2a and b, en-
dogenous protein levels of IRAK1 were high in most cell
lines. Considering the coherence of high expression of
IRAK1 in HCC and most liver cancer cell lines, MHCC-
LM3 and SMMU-7721 were interfered by lentivirus-
mediated siRNA to stably suppress IRAK1 expression.
Two different siRNAs were used to knockdown IRAK1
in both cell lines (Fig. 3a and b). Cells infected with con-
trol lentivirus grew rapidly, whereas cells infected with
lenti-si-IRAK1 had inhibited the cell growth (Fig. 3c). At
the same time, si-IRAK1 was able to augment the chem-
ical drug cisplatin (Cis)-induced apoptosis in SMMC-
Fig. 1 High expression of IRAK1 in HCC tissues (T) comparing with adjacent normal tissues (N). a IRAK1 expression was analyzed by IHC in 33
human liver tissues. Representative IRAK1 staining of de-paraffinized sections of adjacent normal liver (N) and HCC tumor (T) tissues. b RT-PCR
analysis of IRAK1 mRNA in HCC tumor tissues. c Western Blot analysis of IRAK1 in HCC tumor tissues (T1-12) and adjacent liver tissues (N1-12).
d The normalization expression of IRAK1/β-actin. Actin was used as a loading control
Fig. 2 High expression of IRAK1 in different HCC Cell lines. a Western Blot analysis of IRAK1 in different HCC cell lines. b The normalization
expression of IRAK1/β-actin
Li et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:140 Page 4 of 10
7721 or MHCC-LM3 cell lines as shown in (Fig. 3d).
Moreover, in the presence of cisplatin (Cis) or epirubicin
(ADM), si-IRAK1 diminished the nuclear protein levels
of NF-kB/p65 (Fig. 3e). Additionally, we detected the
protein levels of p-IRAK1 (T209) in MHCC-LM3-
SiIRAK1-1 and SMMU-7721-SiIRAK1-1 cell lines and
found that the p-IRAK1(T209) levels were decreased
as down-regulation of IRAK1 (Fig. 3f ). Therefore, we
assumed that down-regulation of IRAK1 slowed prolifera-
tion and induced apoptosis mainly through phospho-
IRAK1 status [14, 16].
Inhibition of p-IRAK1 impeded cell proliferation
and migration
To further study whether p-IRAK1 (T209) contributes
to HCC cells proliferation, the inhibitor of IRAK1/4,
which selectively inhibits the activities of IRAK1 and
IRAK4, was used to repress the activity of IRAK1 in
SMMU-7721 and HepG2 cell lines. Sensitivity of
IRAK1/4 inhibitor was evaluated by treating cells with
serial dilutions of the drug for 5 days and then analyz-
ing cell growth by CCK-8 assays. As displayed in Fig. 4a,
phosphorylation of IRAK1 was significantly inhibited,
Fig. 3 Knockdown of IRAK1 inhibited proliferation and induced apoptosis in HCC cells. a Western Blot analysis of IRAK1 in MHCC-LM3 and
SMMU-7721 cell lines after IRAK1 knockdown. b The normalization expression of IRAK1/β-actin. c The proliferation curves of MHCC-LM3 and
SMMU-7721 cell lines after IRAK1 knockdown. d Apoptosis analysis of MHCC-LM3 and SMMU-7721 cell lines with the stimulation of cisplatin
(Cis, 25 μg/ml). e The nucleocytoplasmic separation analysis of SMMU-7721 cell lines under the stimulation of cisplatin (Cis, 25 μg/ml) or epirubicin
(ADM, 5 μg/ml). f Western Blot analysis of p-IRAK1 (T209) after IRAK1 knocked down. NC: control cell lines; SiIRAK1-1: IRAK1 knockdown cell lines with s1
fragment sequence; SiIRAK1-2: IRAK1 knockdown cell lines with s2 fragment sequence; s1, s2: different shRNA fragments in si-IRAK1 lentivirus. * P < 0.05
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which led to impaired proliferation of both cell lines in
a dose-dependent manner. However, it was noted that
the p-IRAK1 (S376), which might not be the main
phosphorylated form in liver cancer cell lines, was al-
most not expressed in SMMU-7721 and HepG2 cell
lines. After the inhibition of p-IRAK1 (T209) in four
different cell lines, including SMMU-7721, HepG2,
PVTT and PLC/PRF/5, the proliferation rates were
greatly attenuated as showed in Fig. 4c, especially in the
SMMU-7721 and HepG2. In addition, the colony for-
mation analysis of SMMU-7721 and HepG2 cells with
the IRAK1 inhibitor (0, 10 μM and 20 μM) for 48 h fur-
ther confirmed the role of p-IRAK1(T209) in promot-
ing HCC proliferation (Fig. 4d). It implicated that
IRAK1 enhances proliferation in human HCCs mainly
depending on its phosphorylation form (T209).
As is known, migration is crucial for HCC progression
[32]. In this study, we further analyzed the effect of
IRAK1 activity on HCC migration. As the results in
Fig. 4b, the IRAK1/4 inhibitor (20 μM) decreased the
number of migrated cells in SMMU-7721 cells, revealing
that IRAK1 improves HCC migration.
Inhibition of p-IRAK1 lessened cell cycle arrest but
increased apoptosis in HCC cells
Generally, cell proliferation is closely corresponding with
the regulation of cell cycle. However, whether the inhib-
ition of p-IRAK1 affected the cell cycle was unknown.
Fig. 4 The inhibition of p-IRAK1 attenuated proliferation in HCC cells. a The protein levels of p-IRAK1 and total IRAK1 in SMMU-7721 and HepG2
with IRAK1/4 inhibitors (0, 10 μM, 20 μM). b Cell migration analysis in SMMU-7721 cell lines with IRAK1/4 inhibitors (0, 20 μM) treatment for 24 h.
c The proliferation analysis in four different cell lines with IRAK1/4 inhibitors (0, 10 μM, 20 μM) for 1–5 days. d Colony formation analysis in
SMMU-7721 and HepG2 cells with IRAK1/4 inhibitor (0, 10 μM and 20 μM) for 48 h
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We further determined whether the inhibition of p-
IRAK1 affected cell cycle distribution using flow cytom-
etry. In Fig. 5a and b, IRAK1/4 inhibitor treatment (0,
10 or 20 μM) for 24 h or 48 h led to a decrease in the
percentage of cells in S phase. Moreover, IRAK1/4 in-
hibitor treatment at the concentration of 20 μM also
caused apoptosis at 24 h and 48 h in SMMU-7721 cells
(Fig. 5c), suggesting the anti-apoptosis role of IRAK1 in
liver cancer.
The proliferation promoting of IRAK1 in subcutaneous
tumor in vivo
To further study the promoting-tumor effects of IRAK1 in
vivo, we employed SMMU-7721 HCC exnograft models.
Fig. 5 The IRAK1 inhibitor arrested the cell cylce and induced apoptosis in HCC cells. a Flow cytometry assays of cell cycle arrest in SMMU-7721
cell line, with treatment of IRAK1/4 inhibitors (0, 10 μM, 20 μM) for 24 h and 48 h and staining with PI. b The fractions of cells in each phase of
the cell cycle including G0/G1, S and G2/M phases. c Flow cytometry assays of cell apoptosis in SMMU-7721 cell line, with treatment of the
IRAK1/4 inhibitor (20 μM) for 24 h and 48 h and staining with Annexin V and PI
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SMMU-7721-SiIRAK1-1 cells were injected subcutaneously
into the flanks of nude mice. As presented in Fig. 6a and b,
the average tumor volumes and weights in the SMMU-
7721-SiIRAK1-1 groups were smaller than those in the NC
control. Additionally, the immunohistochemical staining of
Ki-67 also showed that shIRAK1 delayed SMMU-7721 cell
proliferation in HCC xenograft model (Fig. 6c).
Moreover, based on SMMU-7721 HCC xenograft
model, IRAK1/4 inhibitor treatment was also used to
investigate the pro-tumor effects of IRAK1 in vivo.
SMMU-7721 cells were injected subcutaneously into
the flanks of nude mice. After the palpable xenograft
tumors were established, the mice were randomly
assigned into treatment with IRAK1/4 inhibitor or
DMSO (control group). As shown in Fig. 6d, the
average tumor volumes and weights in the IRAK1/4
inhibitor-treated groups were also smaller than those
in the DMSO groups (p < 0.05). Mice treated with in-
hibitor showed no obvious signs of toxicity due to no
difference among body weight, food and water intake,
activity during treatment.
Discussion
The pathogenesis of HCC is complex and diverse, in-
volving different signal pathways, such as Wnt [33, 34],
MAPK [30, 35, 36] and PI3K/AKT [31]. Recent studies
also showed that inflammation signal pathways were
closely related to tumorigenesis and development of
HCC [37, 38]. As IRAK1 plays a key role in the TLRs/
IL-1 signaling pathway by activating the downstream of
NF-kB, the functions of IRAK1 in different tumors have
been wildly focused. In acute myeloid leukemia (AML),
over-expressed IRAK1 and universal activation were fre-
quent [21]. In the melanoma cell lines, both IRAK4 and
IRAK1 are highly expressed and activated, and promote
primary melanoma progression [22]. IRAK1 has been
proved as the therapeutic target for lung cancer [23, 24].
Moreover, a recent study showed over-expression of
IRAK1 in breast cancer and demonstrated its potential
target for triple-negative breast cancer (TNBC) metasta-
sis to overcome paclitaxel resistance [26]. Christian
Pilarsky et al. reported that IRAK1 gene was over-
expressed in 10 kinds of cancers, including liver cancer,
Fig. 6 Inhibition of IRAK1 attenuates tumor growth in subcutaneous HCC models. a Xenografted tumor of SMMU-7721 cell lines stably
transfected with lentivirus-delivering shRNA for IRAK1 (shIRAK2) in nude mice. b The graph shows changes in the volume or weight of tumors. The
data are the mean ± SE (n = 4). c The Ki67 staining of Xenografted tumor (X100 and X200). d The graph shows changes in the volumes or weights of
tumors. The data are the mean ± SE (n = 4). SMMU-7721 cell lines were implanted subcutaneously in mice and allowed to grow until the tumors
reached a size of approximately 150 mm3. Xenografted mice were randomized and injected i.p. with 2.12 mg/kg IRAK1/4 inhibitor 4 times per week.
Two weeks later, the average tumor volumes and weights of the IRAK1/4 inhibitor group were analyzed comparing with the control group.
Tumor volumes from two groups were analyzed by two-way ANOVA analysis (*p < 0.05). The graph shows individual tumor volume (t-test, *p < 0.05)
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but there was no further investigation of the function of
IRAK1 [39].
Due to unrestrained proliferation is an important
characteristic for most malignant tumors including
HCC [40, 41], it is meaningful to study the related
mechanism and seek a new therapy strategy. In this
study, frequently high expressions of IRAK1 in HCC
tissues and liver cancer cells were confirmed, revealing
the crucial role of IRAK1 in HCC development. We fo-
cused on the effect of IRAK1 on cell proliferation, and
found the promotive role of IRAK1 for cell proliferation by
regulating cell cycle. Suppression of IRAK1, by either siR-
NAs or the pharmaceutical IRAK1/4 inhibitor, lessened cell
proliferation in HCC cell lines in vitro and HCC xenograft
tumor growth in vivo. A recent research of breast cancers
[26] showed that over-expression of IRAK1 could promote
TNBC growth through regulating NF-kB-related cytokines
secretion. However, in liver cancer, our data were more
prone to its regulation about S phase in cell cycle. Next,
more efforts will be focused on the detail mechanism of
IRAK1 in the cell proliferation in liver cancer.
Chemical inhibition of IRAK1 in melanoma cells re-
sulted in increased apoptosis in vitro and in vivo [22].
Adam et al. [42] also discovered that genetic or pharma-
cologic inhibition of IRAK1 attenuated ERK1/2 pathway
through TRAF6 and induced cell apoptosis in head and
neck cancer cell lines. Combination increased apoptosis
and reduced migration by IRAK1/4 inhibitor in HCC
cell lines, IRAK1 is postulated to promote HCC progres-
sion by controlling HCC cell proliferation and apoptosis.
The pharmaceutical IRAK1/4 inhibitor has already
been frequently used for acute myeloid leukemia (AML)
treatments [21]. Our work further discovered that
IRAK1/4 inhibitor as a novel strategy for HCC therapy.
The high expression (mRNA and protein) of IRAK1 as
well as activated IRAK1 (T209) observed in myelodysplas-
tic syndrome, acute myeloid leukaemia [19, 20], melan-
oma [22] and HCC [8] showed the probable correlation
between IRAK1 and its phosphorylated activation. Since
the function of IRAK1 mainly relies on its phosphorylated
status in most tissues and cells [14, 16], in this study,
si-IRAK1 or the IRAK1/4 inhibitor suppressed
phosphor-IRAK1 protein levels, indicating that high
expression of IRAK1 in HCC promotes cell prolifera-
tion and anti-apoptosis mainly through its phosphory-
lated status. Moreover, the data from xenograft of
HCC cell line confirmed this possibility. Of course, it
still remains further study on the molecular mechan-
ism about this association observed in HCC.
Conclusions
We revealed the important role of IRAK1 in promoting
HCC growth and apoptosis, and discovered it as a candi-
date target for HCC treatment. More details about the
mechanisms and personalized therapy need to be further
studied in future.
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